Mobile Site ›
Print Friendly View

Test ID: BPG2    
11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Measurement of 11 beta-prostaglandin F2 alpha in urine is useful in the evaluation of patients suspected of having systemic mast-cell disease

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Prostaglandin D(2) (PGD[2]) is generated by human mast cells after they are activated via the IgE receptor or by calcium ionophore. In addition to mast cells, activated alveolar macrophages and platelets also produce and secrete PGD(2). There are a large number of metabolic products of PGD(2), the most abundant is 11 beta-prostaglandin F2 alpha.(1)

 

While the most definitive test for systemic mast-cell disease is bone marrow examination, measurement of mast-cell mediators in blood or urine is less invasive and is advised for the initial evaluation of suspected cases. Elevated levels of tryptase, N-methylhistamine or 11 beta-prostaglandin F2 alpha are consistent with the diagnosis of systemic mast cell disease.(2)

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

>1,000 ng/24 hours is considered elevated.

Interpretation Provides information to assist in interpretation of the test results

Levels of 11 beta-prostaglandin F2 alpha >1,000 ng/24 hours are consistent with the diagnosis of systemic mast-cell disease.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Elevated levels of 11 beta-prostaglandin F2 alpha in urine are not specific for systemic mast-cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast-cell proliferation.  

 

Systemic mast-cell disease is a heterogeneous disease, and some patients may not have elevated levels of 11 beta-prostaglandin F2 alpha in urine.

Supportive Data

In studies performed at Mayo Clinic, elevated levels of 11 beta-prostaglandin F2 alpha in urine were found in 16 of 17 patients with systemic mast cell disease.

 

Misoprostol (Cytotec) does not cross-react in this assay.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Roberts LJ, Sweetman BJ, Lewis RA, et al: Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980;303:1400-1404

2. Metcalfe DD: Mastocytosis syndromes. In Allergy Principles and Practice. Vol II. Fourth edition. Edited by E Middleton Jr, CE Reed, EF Ellis, et al. St. Louis, Mosby Yearbook, Inc, 1993, pp 1537-1551

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test